Pacific Biosciences of California PACB Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacific Biosciences of California's contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacific Biosciences of California's contract liabilities?
- Pacific Biosciences of California (PACB) reported contract liabilities of $3.55M in Q1 2026.
- How has Pacific Biosciences of California's contract liabilities changed year-over-year?
- Pacific Biosciences of California's contract liabilities decreased by 39.3% year-over-year, from $5.86M to $3.55M.
- What is the long-term trend for Pacific Biosciences of California's contract liabilities?
- Over 5 years (2020 to 2025), Pacific Biosciences of California's contract liabilities has grown at a 20.2% compound annual growth rate (CAGR), from $1.57M to $3.93M.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.